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Background: Chronic airway diseases pose a big challenge to health systems in most developing countries,
particularly in Sub-Saharan Africa. A diagnosis for people with chronic or persistent cough is usually delayed because of
individual and health system barriers. However, delayed diagnosis and treatment facilitates further transmission, severity
of disease with complications and mortality. The objective of this study is to assess the cost-effectiveness of the
practical approach to lung health strategy, a patient-centred approach for diagnosis and treatment of common
respiratory illnesses in primary healthcare settings, as a means of strengthening health systems to improve the quality
of management of respiratory diseases.
Methods/design: Economic evaluation nested in a cluster randomised controlled trial with three arms will be
performed. Measures of effectiveness and costs for all arms of the study will be obtained from the cluster randomised
controlled clinical trial. The main outcome measures are a combined rate of major respiratory diseases milestones and
process indicators extracted from the practical approach to lung health strategy. For analysis, descriptive as well as
regression techniques will be used. A cost-effectiveness analysis will be performed according to intention-to-treat
principle and from a societal perspective. Cost-effectiveness ratios will be calculated using bootstrapping techniques.
Discussion: We hope to demonstrate the cost-effectiveness of the practical approach to lung health and informal
healthcare providers, see an improvement in patients’ quality of life, achieve a reduction in the duration and occurrence
of episodes and the chronicity of respiratory diseases, and are able to report a decrease in the social cost. If the practical
approach to lung health and informal healthcare provider’s interventions are cost-effective, they could be scaled up to
all primary healthcare centres.
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Chronic airway diseases (CAD) which include tubercu-
losis, asthma and chronic obstructive pulmonary disease
(COPD) represent a major disease burden to most devel-
oping countries, particularly in Sub-Saharan Africa [1-4].
COPD and asthma are estimated to affect 64 million and
235 million people worldwide, respectively [3]. A diagnosis
for people with chronic or persistent cough is usually de-
layed because of individual and health system barriers.
Unfortunately, delayed diagnosis and treatment of COPD
and asthma facilitates further TB transmission, severity of
disease with complications and mortality. In the latest es-
timates, COPD was the fourth leading cause of deaths in
2004, and in 2030, it is projected to become the third lead-
ing cause, with 5.8 million or 8.6% of the total deaths [3].
It has been estimated that, asthma morbidity and mortal-
ity accounts for around 1% of all disability-adjusted life
years (DALYs), equivalent to 16 million DALYs lost per
year worldwide [3]. A crucial point is that all respiratory
diseases, if not diagnosed, treated and managed timely
and correctly, are problematic for individuals and health
systems alike [5].
The WHO initiated a practical approach to lung health
(PAL) strategy in early 1998 [6], a patient-centred ap-
proach to improve the quality of diagnosis, treatment and
management of common respiratory illnesses in primary
healthcare settings. The PAL seeks to strengthen health
systems response to respiratory diseases by standardising
service delivery through development and implementation
of clinical guidelines and managerial support within the
peripheral health system establishments. It is intended
to coordinate delivery of health services among differ-
ent levels of healthcare providers in the health system
and between tuberculosis control and general health
services [7].
Recent original studies and systematic reviews of the
PAL strategy in high- and middle-income countries have
demonstrated major benefits for implementing PAL on
COPD [8,9]. The benefits of using the strategy include:
marked improvement in TB case detection; prescription
of bronchodilators and inhaled corticosteroids for asthma
and COPD; reduction in complicated COPD cases. Con-
trary to high- and middle-income countries context,
there is no clear information on the types of treatment
available for both COPD and asthma that can help to
control symptoms and slow disease progression in low-
income countries. Similarly, current information on the
cost-effectiveness of PAL is limited to randomised trial
results from developed countries. Less information is
available on health effects and costs of PAL interventions
at population level in low-income countries [10-16]. Ac-
cordingly, the aim of this study is to provide evidence on
the most cost-effective PAL interventions for COPD and
asthma management in Malawi.In most low-income countries, informal healthcare pro-
viders—a plethora of independent and largely unregulated
healthcare practitioners—are a vital source of health care
and often represent the first point of care for most pa-
tients [17,18]. Despite some challenges that informal pro-
viders pose to policy makers in the health sector, they also
present an opportunity to address several high-priority
health system concerns. It has been documented that in-
formal providers fill gaps in formal healthcare provision
and effectively reach traditionally hard to reach popula-
tions located in rural and remote areas [17,18]. This sug-
gests that, with proper strategies, informal providers can
potentially be harnessed to expand access to respiratory
care through well-supported referral systems. This is in
line with Van Den Boom et al. (2010) who have argued
that PAL adaptation at a country level is a must and has
to take into account the epidemiological, socioeconomic
profile, national health policies, the structure of the health
system and available health resources, especially at pri-
mary healthcare level [5].
Given that the informal health sector in Malawi is larger,
a PAL strategy including informal health sector providers
may lead to higher compliance to PAL intervention and
thus a lower rate of COPD and their costs. This will be
tested in this study. It is expected that an increased adher-
ence to the guidelines’ recommended in PAL and PAL +
informal healthcare providers will increase case finding
and reduce the number of major TB, COPD/asthma com-
plications. By reducing the number of major COPD/
asthma complications, we expect a reduction in healthcare
costs (e.g. hospitalisation, referral, medication), patient
and family costs, costs of lost production and costs in
other sectors.
Objectives
The objective of this study is to assess the cost-
effectiveness of the PAL strategy on CAD, asthma, bron-
chiectasis and TB, including the involvement of informal
healthcare providers compared to a common strategy of
treating only those with TB and not chronic airway dis-
ease. The principal research question is: Does the adop-
tion of PAL and PAL + informal healthcare provider
model of CAD management in primary healthcare set-
tings leads to improved health outcomes and cost-
effective management of patients with CAD, compared
to routine primary health care?, and specific health eco-
nomics research questions are:
1. What is the impact of PAL or PAL + informal
healthcare providers on patient and health system
costs?
2. What is the cost-effectiveness of PAL and PAL +
informal provider strategies to diagnose, treat and
manage CAD and TB as a routine clinical practice?
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the PAL or PAL + informal provider’s strategies?
Methods and design
Ethical approval
Ethical approval for the study was granted in Malawi by
College of Medicine Research and Ethics committee
(COMREC) in September 2013 and Liverpool School of
Tropical Medicine Research Ethics Committee in July
2014.
Study design
An economic evaluation involving three arms to compare
cluster randomised controlled trial (CRCT), with random-
isation at the health centre level. The randomization will
be across 27 clusters, 9 clusters per arm, in two districts in
Malawi. Health centre recruited to the study will be ran-
domised to one of the three arms as indicated in Figure 1.
Health economics data collection will be conducted
before and after the implementation of the intended in-
terventions to quantify the additional costs (savings) and
health gains associated with the implementation of PALFigure 1 Effect of PAL strategy on treatment received by patients.and PAL + informal healthcare providers as compared
with the status quo. Specific secondary aims will be to
determine whether the incremental costs of PAL and
PAL + informal healthcare provider strategy are out-
weighed by incremental cost savings associated with any
changes in practice (i.e. whether implementing PAL for
CAD is cost saving as compared PAL + informal health-
care providers) and to determine whether PAL strategy
dominates PAL + informal healthcare providers alone
(i.e. less costly but of at least equivalent effect). Com-
parison will be made between baseline and final survey
to estimate incremental cost-effectiveness ratios (ICERs)
comparing the intervention with the control arms in
terms of primary outcome measures (proportion of the
population with a chronic cough on salbutamol/cortico-
steroid inhaler indicated in their health passports) and
costs.
Study population
The participants of this study will be health centres, infor-
mal healthcare providers, patients and caregivers. Inter-
viewers will explain to all participants that involvement in
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at any point in time and to ask any questions. Information
about the study will be read to all participants and pro-
vided in hard copy. All consenting participants will be
asked to sign two standard consent forms (that is one for
the interviewee and one retained by the interviewer).
a) Health centres
Two types of health centres are included in the
study: public and private-not-for-profit belonging to
the Christian Health Association of Malawi (CHAM)
health centres. All health centres in the eligible cluster
will be enumerated and informed of the proposed
study. Health centres will be selected at random
and asked to provide consent prior to cluster
randomisation. All health centres involved in the
diagnosis and treatment of suspected cases of
COPD are eligible to participate in the study.
b) Informal providers
Informal providers function within a broad and
complex health system and have established some
ties to other parts of the system. In particular, many
informal providers have some ties with formal sector
health providers. Although the nature of these
interactions differs greatly by location, informal
providers seem to have strong local roots and
well-established long-running practices. Importantly,
they are well regarded and trusted members of
the community that they serve. In Malawi, for
instance, more than half of the informal providers
were born and live in districts where they practice.
These informal providers operate as volunteers
and traditional healers and offer advantages
including greater flexibility, value, convenience
and privacy.
c) Patients and caregivers
The inclusion of patients and their caregivers in the
study is justified on the basis that these are often the
only common factor moving across sites of care, and
they are the most appropriate targets for an
intervention designed to improve care pathways.
Sampling
This study is planned to explore the difference in patient
costs at baseline and study end, after the PAL and PAL +
informal healthcare provider interventions have been im-
plemented. At baseline, we will capture costs incurred by
all patients who have CAD diagnosis in their passport.
Based on the Baseline Community Survey, the expected
number of patients with CAD/TB diagnosis in their pass-
port at baseline is 135. The main effect size of the inter-
ventions is to be captured by the endline survey. The
baseline survey is primarily intended to inform the sample
size and design of the endline survey. This implies thatpower calculation and the sample size at the end of the
study will be informed by estimation of patient-level vari-
ation in costs from baseline results. At a minimum, it will
repeat sampling as indicated for baseline community
survey.Trial design
Patients allocated to the control arm will receive usual
clinical care, an individual intervention based on the appli-
cation of the “essential health package guidelines”. These
guidelines have been documented in the Ministry of
Health—essential health package policy document. In
addition to the standard intervention as in the control
arm, patients allocated to the intervention arms 1 and 2
will be treated at facilities that have had their staff trained
on PAL strategy and other in facilities that have a PAL
strategy linked to informal healthcare providers in the re-
ferral system as illustrated in Figure 1.Outcome measures
Primary outcomes
1. Proportion of the population with a chronic cough
who have a diagnosis of TB or airway disease(s)
recorded in their health passports.Secondary outcome
1. Proportion of the population with a chronic cough
or salbutamol/corticosteroid inhaler indicated in
their health passports.
2. Proportion of the population with a chronic cough
with a diagnosis of TB or airway disease among
patients with chronic cough attending primary
healthcare recorded in patient registers at
intervention facilities.
3. Patient costs incurred in healthcare seeking by
individuals with chronic cough as well as health
system resource use.Additional outcome measures
The study also proposes obtaining health-related quality
of life data, as measured by the Euroqol (EQ-5D-3 L)
questionnaire. Data will be collected over the study period
and used to generate quality-adjusted life years (QALYs)
for each treatment arm. The advantage of using generic
preference-based measures like the EQ-5D is that they are
easy to use and can be incorporated into data collection
systems easily, with little additional burden for respon-
dents. The generic nature of EQ-5D makes them relevant
to all patient groups and aids standardisation and compar-
isons between patient groups [19-21].
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Economic costs will be collected from a societal perspec-
tive and will consider both the healthcare resource re-
quirements and patient expenses associated with each
treatment group. Specifically, we will collect data on
three resource use: intervention costs, which include all
the resources required to organise and implement CAD
clinical practice; other healthcare service costs, which in-
clude the use of all health centres over the course of the
trial, including both drugs and medical supplies; patient
out-of-pocket expenses, which includes the individual’s
own time in the treatment process and associated travel
expenses. Healthcare service costs will be incurred at 18
health centres included in the intervention arms. Patient
costs that will be estimated are those incurred in seeking
services for CAD health care. All costs will be inflated to
2013 values, using the relevant consumer price indices
from the International Monetary Fund (IMF), and
converted from Malawi Kwacha to United State Dollar
(US$) using relevant conversion factors from OANDA.
a) Intervention costs
The project-related costs incurred between 2014 and
2015 by the two agencies implementing the project for
advancing CAD-related health services in low-income
settings, LSTM and REACH TRUST. The research cost
associated with baseline and final surveys and research-
specific technical assistance will be disaggregated from
all capital and recurrent programme costs. Cost will be
categorised as research or programme cost and by
study arm and district and captured using an excel
spreadsheet.
b) Health system costs
Primary data on provider’s costs will be collected from
all health centres in the intervention arms of the study.
For incremental cost analysis purposes, resource use in
the control arm will be estimated basing on cost of
standard care, using information from budget and finan-
cial records maintained by health centres in the control
arm and their related district hospitals. In the interven-
tion arms, data on utilisation of CAD health services,
the associated consumption of drugs and medical sup-
plies and time allocated to CAD care by staff in the
health centre will be collected from individual patient
records and pharmacy logs and in time allocation inter-
views with the health centre care providers and captured
on Excel worksheet. Unit costs for healthcare resources
will be derived from local and national sources and per-
formed in line with best practices [22-27].
c) Patient costsData to estimate patient costs will be collected in two
stages. First, through a baseline survey before the imple-
mentation of the intervention capturing costs for all pa-
tient with CAD diagnosis in their health passport.
Second, a final survey 1 year after the implementation of
the intervention capturing costs incurred to get treat-
ment. The surveys will include questions on fees paid to
the health system, drugs and laboratory test costs and
transport, food and accommodation costs incurred as a
result of the treatment process as well as time lost from
economic activities due to illness or care-seeking. The
STOP-TB costing tool will be adapted for use. Table 1
summarises cost data collection procedures.
Measure of resources and costs
The cost analysis will be conducted using a bottom-up
approach, whereby we will determine necessary amount
of each resource: personnel, equipment, material etc.
and the costs per unit of each resource, then average
cost will be calculated for each particular type of cost.
An overview of the costs that will be measured and the
corresponding sources can be found in Table 2.
Medical direct costs include those attributable to
healthcare visits for treatment of CAD: the cost of PAL
strategy utilized and training provided to healthcare pro-
viders; visits to primary healthcare facilities, to specialists
and to rehabilitation services; number of essential tests;
cost of medicines and disposable supplies and hospital-
isation for acute episodes of asthma or COPD.
Non-medical direct costs will include home help re-
ceived as a result of morbidity related to COPD, patient
and guardian time directly related to the intervention
(time spent getting to the facility, waiting room and
intervention). Indirect costs include loss of productivity
and will be calculated on the basis of time off work (ab-
senteeism) as well as reduced productivity at work (pres-
enteeism). The patients will be asked to quantify how
much work was actually performed during regular hours
and quality of this work compared to now. Cost will be
calculated in international US$ following the PPP.
Data analysis
Hypothesis being tested in the study are: 1) The prac-
tical approach to lung health strategy will decrease the
incidence of CAD-related diseases and reduce the costs
related to these diseases on both individuals and the
health system. Thus, the PAL approach is cost-effective
compared to the standard practice; 2) using both the
practical approach to lung health strategy and involve-
ment of informal providers through a referral system
will be more cost-effective compared to the practical
approach to lung health strategy only.
The effect of the two interventions compared with con-
trol will be analysed with methods appropriate for cluster
Table 1 Summary of data collection procedure
Type of cost When Where How How many
Intervention Ongoing-from the inception
to the end of project
REACH TRUST and LSTM Project budget and expenditure
records
All data available
Healthcare service Ongoing-from the inception
to the end of project
Health centres in the
intervention arms
Health centre budget and
government documents
18 health centres
Patient At baseline and at the end
of project
Patient home or convenient
location
Patient cost questionnaires
administered at the begin and
end of project
135 at baseline, sample size
at endline dependent on
baseline results
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strategy with regard to all outcome measures (primary,
secondary and QALYs), descriptive as well as regression
techniques will be used. The analysis will include compari-
son of the three arms, as well as a multilevel analysis. The
later will incorporate the levels of health worker, patient
and time management. The process information regarding
to what extent healthcare professional used PAL strategy
will allow us to analyse the relationship between the use
of PAL and the primary and secondary outcome measures.
Process information will also give us insight into the ex-
perience of participants (health workers and patients), on
both satisfaction and feasibility with the PAL strategy and
other implementation activities.Table 2 Measures of health systems and patient cost
Measurements of cost
Type of cost Expenditures Specification S
u
Medical direct costs Primary healthcare
consultations
Medical
practitioner
S
c
Facility nurse A
q
Hospitalisation Varied P
Secondary care
consultation
Other specialist S
c
Diagnostic tests Radiology and laboratory S
c
Pharmaceutical supplies Inhalers and antibiotics P
Additional medical services Rehabilitation and other
therapies
P
Material provided in PAL
intervention
Leaflets and booklets P
Equipment used in
intervention
Sputum containers P
Pulse oximeter
Nebulizer
Spirometer
Non-medical direct costs Aid to patients who
face disabilities
Aid in household S
Transport cost e.g. referrals S
Indirect costs Cost of lost Absenteeism S
ProductivityThe time horizon for inclusion of relevant costs and
consequences is set as 12 months, consistent with the
endline survey from the CRCT. That is to say, the eco-
nomic evaluation is explicitly within trial and that any
subsequent extrapolation beyond the trial period will be
treated as a separate research task. Similarly, because of
the short period of the study, we will not discount costs or
benefits [22-26].
Economic evaluation
For economic analysis, cost-effectiveness ratios will be cal-
culated based on the primary outcome (i.e. the cost per
case of suspected CAD that received treatment as recom-
mended in the PAL guidelines) as well as a range ofource of resources
sed
Source of cost Cost calculation
elf-reported and
omparison
Healthcare provider
nswers in
uestionnaires
rovider Healthcare provider Resource × unit cost
elf-reported and
omparison
Healthcare provider Number of visits × tariff
elf-reported and
omparison
Healthcare provider Number of visits × tariff
rovider Standard pharmaceutical
prices
Medicine bought × price
rovider Healthcare provider Service provide × tariff
rovider Provider and production
cost
Number of material ×
price
rovider Provider and market
prices
elf-reported Patient Hours of aid × price
per aid
elf-reported Patient Distance × price
elf-reported Patient
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ledge. Cost-effectiveness will be calculated for each
comparison and will be expressed as incremental cost ef-
fectiveness ratios (ICERs). In addition to ICERs, we will
also calculate the cost per QALY. The economic evalu-
ation (cost-effectiveness) will be performed according to
the intention-to-treat principle and from a societal per-
spective. Healthcare costs (costs of diagnosis, treatment
and management), costs in other sectors, patient and fam-
ily costs and costs of production losses will be included.
ICER will be estimated using bootstrapping techniques
and graphically presented on cost-effectiveness planes.
One-way and multi-way sensitivity analysis will be per-
formed in order to assess the robustness of the results and
examine the effect of varying uncertain variables on study
findings. A full analysis plan will be reviewed and agreed
before the data are analysed.
Discussion
This study addresses an important problem, because
CAD is among the main causes of high mortality and
morbidity in communities where people lack access to
diagnosis, treatment and management of the disease.
This indicates that there is room for improvement of the
diagnosis, treatment and management of CAD for this
group of people.
PAL strategies aim to promote evidence-based prac-
tice, improve patient outcome and allow more efficient
use of scarce resources. It is expected that an increased
adherence to the guidelines’ recommended in PAL and
PAL + informal healthcare providers will reduce the
number of major COPD/asthma complications. By re-
ducing the number of major COPD/asthma complica-
tions, we expect a reduction in healthcare costs (e.g.
hospitalisation, referral, medication), patient and family
costs, costs of lost production and costs in other sec-
tors. Estimating the size of this cost reduction is an es-
sential part of this study.
This study will also allow us to ascertain which elements
of a multifaceted PAL strategy and PAL strategy + infor-
mal providers can be particularly associated with suc-
cessful implementation of the PAL guidelines on CAD
in low-income setting. The results of our study can
contribute to more knowledge about the effectiveness
of PAL strategy on CAD diagnosis, treatment and man-
agement in low-income country settings.
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